Cancer Profiling and Pathways: Technologies and Global Markets

Cancer Profiling and Pathways: Technologies and Global Markets

  • January 2014
  • 362 pages
  • Report ID: 298002
STUDY GOALS AND OBJECTIVES

This BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and pathways. This report analyzes in detail the cancer profiling and tools markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer profiling methods, strengths, weaknesses, opportunities and challenges, major issues involved in the research and development (R&D) of more effective cancer profiling techniques, and new cancer therapeutics in development and in clinical trials.

REASONS FOR DOING THE STUDY

Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Life Technologies, Agilent and Affymetrix, respectively, are maintaining their leads in the quantitative real-time PCR and microarray market segments. Understanding the multivariate nature of cancer and drug response also depends on molecular profiling at epigenetic, genetic and protein levels. A major challenge is to develop an understanding of this multivariate dysregulation, with respect both to how it arises from diverse genetic mutations and to how it may be ameliorated by prospective treatments. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market.

SCOPE OF REPORT

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.
Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.
The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.
This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also looks into recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

INTENDED AUDIENCE

This report is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies and segments, important trends in technology development, next-generation technologies, major opportunities and market shares of key players and innovative drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. As market needs change with progress, the value of the information provided from microarrays, sequencing and qRT-PCR has become more interesting for markets outside of basic life-science research. In oncology-expression pattern profiling, comparing expression in normal and cancer tissues shows an unexpected greater reliability in classifying cancer types than the signatures of protein-coding genes. Researchers have also successfully classified poorly differentiated tumors using expression profiles. Along with their diagnostic potential, cancer-profiling techniques have also reportedly proven to be of prognostic value to predict survival among cancer patients and poor responsiveness to adjuvant chemotherapy and other drugs.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news, and developments and through access to paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of cancer, incidence, development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, current product growth, etc. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on prostate cancer assay development and previously marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific-related journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were contacted to obtain data for this study. Included were manufacturers and end users of products, which included pharmaceutical and biotechnical industries, research institutes, etc. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.

REPORT HIGHLIGHTS

The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.

This report provides:
• An overview of the global market for cancer profiling and biomarker studies
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Discussion of products in this market, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market
• Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
• Identifications of important cancer profiling techniques, market share by type of products on the market and market share by company, as well as types of cancers and biomarkers
• Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products
• Comprehensive company profiles of key players in the market.
Country=World Industry=Genomics ParentIndustry=Biotechnology Date=201401 Topic=MarketReport Publisher=BCCResearch Price=5000